| Identification | Back Directory | [Name]
benzo[d]oxazole-6-carboxylic acid | [CAS]
154235-77-5 | [Synonyms]
6-Benzoxazolecarboxylic acid
Benzoxazole-6-carboxylic Acid
benzo[d]oxazole-6-carboxylic acid
1,3-Benzoxazole-6-carboxylic acid
1,3-Benzoxazole-6-carboxylic acid 97% | [Molecular Formula]
C8H5NO3 | [MDL Number]
MFCD09954949 | [MOL File]
154235-77-5.mol | [Molecular Weight]
163.13 |
| Chemical Properties | Back Directory | [Melting point ]
280-290 °C (sublm)(Press: 16 Torr) | [Boiling point ]
350.1±15.0 °C(Predicted) | [density ]
1.455±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [form ]
Solid | [pka]
3.60±0.30(Predicted) | [color ]
Light brown to brown |
| Hazard Information | Back Directory | [Uses]
6-?Benzoxazolecarboxyli?c Acid is a reactant used in the design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as α7 nicotinic acetylcholine receptor agonists. | [in vivo]
Serpin B9-IN-1 (BTCA) inhibits bone metastasis (BM) in multiple tumor metastasis models. Serpin B9-IN-1 (50 mg/kg/d; ip; 14 d) effectively reduced the survival rate and metastasis proportion of metastatic cancer cells in the mouse bone metastasis model with LLC1-BM3 injected into the tail artery (CA)[1].
Serpin B9-IN-1 (300 μg/d; ip; 14 d) effectively delayed the average time to bone metastasis (BM) in the LLC1-BM3 cell group[1].
| Animal Model: | LLC1-BM3 Bone Metastatic Mouse Model by CA injections[1] | | Dosage: | 50 mg/kg | | Administration: | ip; followed after cancer cell injection, injection daily for 14 days | | Result: | Reduced the survival rate and metastasis proportion of metastatic cancer cells
|
| Animal Model: | LLC1-BM3-sr-ctrl Model in Mouse[1] | | Dosage: | 300 μg | | Administration: | ip; once daily for 14 days | | Result: | Delayed the mean time to occurrence of bone metastasis (BM), and lowered the burden of BM in LLC1-BM3-shSB9 cells group.
|
|
|
|